Cold atmospheric plasma: a new strategy based primarily on oxidative stress for osteosarcoma therapy
Osteosarcoma is the most common primary bone tumor, and its first line of treatment presents a high failure rate. The 5-year survival for children and teenagers with osteosarcoma is 70% (if diagnosed before it has metastasized) or 20% (if spread at the time of diagnosis), stressing the need for nove...
| Authors: | , , , |
|---|---|
| Format: | article |
| Publication Date: | 2021 |
| Country: | España |
| Institution: | Universitat Politècnica de Catalunya (UPC) |
| Repository: | UPCommons. Portal del coneixement obert de la UPC |
| Language: | English |
| OAI Identifier: | oai:upcommons.upc.edu:2117/352890 |
| Online Access: | https://hdl.handle.net/2117/352890 https://dx.doi.org/10.3390/jcm10040893 |
| Access Level: | Open access |
| Keyword: | Tissue engineering Osteosarcoma Cold atmospheric plasma Plasma treated liquids Reactive oxygen and nitrogen species Oxidative stress Tumor microenvironment Cancer stem cells Enginyeria de teixits Ossos -- Càncer plasma Àrees temàtiques de la UPC::Enginyeria dels materials |
| Summary: | Osteosarcoma is the most common primary bone tumor, and its first line of treatment presents a high failure rate. The 5-year survival for children and teenagers with osteosarcoma is 70% (if diagnosed before it has metastasized) or 20% (if spread at the time of diagnosis), stressing the need for novel therapies. Recently, cold atmospheric plasmas (ionized gases consisting of UV–Vis radiation, electromagnetic fields and a great variety of reactive species) and plasma-treated liquids have been shown to have the potential to selectively eliminate cancer cells in different tumors through an oxidative stress-dependent mechanism. In this work, we review the current state of the art in cold plasma therapy for osteosarcoma. Specifically, we emphasize the mechanisms unveiled thus far regarding the action of plasmas on osteosarcoma. Finally, we review current and potential future approaches, emphasizing the most critical challenges for the development of osteosarcoma therapies based on this emerging technique. |
|---|